Savara Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Matthew Pauls
- Full Time Employees
- 70
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- The Tannery Yardley PA United States of America 19067
- IPO Date
- Apr 28, 2017
- CIK
- 0001160308
- Website
- savarapharma.com
- Similar Companies
- Business
- Savara Inc. is a clinical-stage biopharmaceutical company specializing in the development of therapies for rare respiratory diseases. The company's primary product candidate is MOLBREEVI, an inhaled recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) delivered via the proprietary eFlow Nebulizer System licensed from PARI Pharma GmbH. MOLBREEVI is in Phase 3 development for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung disease characterized by the accumulation of surfactant in the alveoli, causing impaired gas exchange in the lungs. Savara focuses on developing innovative inhaled therapies that address significant unmet medical needs in rare respiratory conditions. Founded in 2007 and headquartered in Houston, Texas, Savara outsources much of its clinical development and manufacturing operations to specialized vendors and consultants, enabling capital-efficient development of its pipeline. Apart from MOLBREEVI, the company has historically focused on other product candidates like AeroVanc for methicillin-resistant Staphylococcus aureus (MRSA) lung infections in cystic fibrosis patients, although MOLBREEVI remains its lead asset. Savara operates primarily in the United States and Europe, aligning its regulatory efforts with U.S. FDA, European Medicines Agency (EMA), and United Kingdom authorities. In the past two years, Savara has made significant strategic and operational advancements. Notably, it secured a European patent for its MOLBREEVI drug-device combination with PARI Pharma, protecting the proprietary nebulizer-based delivery system. The company plans regulatory submissions for MOLBREEVI’s biologics license application (BLA) re-submission in the U.S. and marketing authorization application (MAA) in Europe and the UK in early 2026. Recently, Savara completed a public offering with full exercise of the underwriters' option, raising approximately $149.5 million to support development and commercialization activities. Additionally, it negotiated a $75 million royalty funding agreement to support the potential launch of MOLBREEVI. Leadership enhancements have been made, including the promotion of Dr. Yasmine Wasfi to Chief Medical Officer, providing regulatory and clinical development expertise essential for navigating approval processes. Savara aims to become a leader in rare respiratory disease therapeutics by advancing innovative medicines targeted at orphan diseases like autoimmune pulmonary alveolar proteinosis, with an emphasis on leveraging inhalation delivery technologies. Its business model involves close collaboration with external specialized partners for manufacturing and clinical operations, focusing on efficient progression of its late-stage pipeline assets to commercialization. This comprehensive profile reflects Savara's current product offerings, operational focus, recent strategic financing, intellectual property developments, and leadership changes as of late 2025.
Company News
BlackRock Inc. Takes $76.97 Million Position in Savara Inc. $SVRA
Algert Global LLC Purchases 464,645 Shares of Savara Inc. $SVRA
Deutsche Bank AG Makes New $5.33 Million Investment in Savara Inc. $SVRA
Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026
Savara Announces New Employment Inducement Grant
Savara Reports Second Quarter 2026 Financial Results and Provides Business Update
Savara: High Potential Binary Bet Cruising To PDUFA After 3 Month Speed Bump
Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041
Here's Why You Should Add Savara Stock to Your Portfolio Now
What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline
Savara Announces New Employment Inducement Grant
Savara Announces Chief Financial and Administrative Officer Transition
Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference
Savara: The Rare Disease Funnel Is Becoming A Commercial Asset
Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thor
Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026
Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonar
Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)